

Application No. 10/005,438  
Response to Nov. 14, 2005 Office Action  
Page 2 of 6

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1-13 (Cancelled)**

14. (Currently Amended) An IFN-Fc hybrid molecule comprising an interferon molecule joined at one end to one chain of an immunoglobulin Fc fragment without any linker between the interferon and the immunoglobulin Fc fragment, and functional IFN-Fc variants having at least 95% identity to SEQ ID NO 1 thereof.
15. (Previously Presented) The hybrid molecule of claim 14, wherein the interferon is interferon- $\alpha$  and is joined at its C-terminal end to the N-terminal end of the immunoglobulin Fc fragment.
16. (Previously Presented) The hybrid molecule of claim 14, wherein the Fc fragment is a gamma-4 chain Fc fragment, and wherein said fragment does not induce antibody-dependent cellular cytotoxicity (ADCC) or activate complement.
17. (Withdrawn) The hybrid molecule of claim 16, wherein a second interferon molecule is joined at its end to the end of the other immunoglobulin Fc fragment chain, thereby forming a homodimer.
18. (Previously Presented) The hybrid molecule of claim 14, wherein the interferon molecule is interferon- $\alpha$ 2a or interferon- $\alpha$ 2b.
19. (Previously Presented) A composition comprising the hybrid molecules of any of claims 14 to 18 for treatment of tumors.

Application No. 10/005,438  
Response to Nov. 14, 2005 Office Action  
Page 3 of 7

20. (Withdrawn) A method of treating a tumor comprising administering to a patient in need of such treatment the hybrid molecule of any of claims 14 to 18.
21. (Withdrawn) A method of treating a tumor comprising administering to a patient in need of such treatment the composition of claim 19.
22. (Withdrawn) The method of claim 20, wherein the tumor size is reduced as a result of such treatment.